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Genetics & Adverse Drug ReactionsPersonalizing Medicine= defining optimal diagnostic, management & 
treatment strategies for the individual patient
Pharmacogenetics Pharmacoecology
-specific tests to prevent 
toxicity (eg. HLA-B*5701 
screening for abacavir
hypersensitivity
-guide dosing of drugs
-HLA and other immune 
markers to guide vaccine 
development and predict 
response
-individualizing the patient’s environment to 
optimize therapeutic outcome
-PK/PD interactions with drugs, herbal medicines 
and nutritional supplements
-food effects on drugs (absorption/bioavailability)
-adherence (cultural & socioeconomic influences)
-intercurrent disease of host state (eg organ failure, 
pregnancy)
-diurnal variation in pharmacokinetics/dynamics
-individual drug taking behaviour
Personalized Prescription
Phillips E, Mallal S   Personalized  Medicine 2009 (in press)Characteristics of Drug Reactions
Classification TYPE A = 
Pharmacological
TYPE B = 
“Bizarre”
Predictable Yes No
Dose Dependent +++ + 
Host Dependent
(Genetic factors)
+ +++
Immunologic basis - +++
Examples Gastrointestinal 
intolerance, seizures with 
penicillin etc
Allergic and 
idiosyncratic 
syndromes, 
hypersensitivity 
syndromesClassification of ADRs
Drug Reaction
Predictable Reactions
(dose dependent)
Unpredictable Reactions
(less dose dependent)
Hypersensitivity/         Pseudoallergic
Immunogenetic
Type I ASA
Type II Vancomycin
Type III Contrast
Type IVa-d
Idiosyncratic
•Reactive
Metabolite
Syndromes
(eg, Drug 
Hypersensitivity
Syndrome)
•Hepatitis
•SJS/TENTYPE B REACTIONS:   Associated Drugs
Anticonvulsants
z phenytoin, phenobarbital, carbamazepine
z lamotrigine
Antimicrobials
z sulfonamides (sulfa antimicrobials), penicillins, dapsone
z nitrofurantoin, minocycline, metronidazole
Allopurinol
Antiinflammatories (eg oxicam-NSAIDS, Valdecoxib)
Antiretrovirals
Alternative medicines 
z Chinese herbals etc.
Antineoplastics
mAbs
z “Ximab” (infliximab, rituximab) > “Zumab” (omalizumab) > 
“Mumab”(adalimumab)Pharmacogenetics
Drug Æ Disease Æ Gene
Dose Dependent Disease
-Drug Efficacy or toxicity 
-Often multifactorial (eg age, gender, 
BMI, concurrent medications)
-Often related to polymorphism(s) in 
drug metabolizing enzymes (eg CYP) 
or pharmacodynamic factors
-eg Warfarin, efavirenz, clopidogrel
Dose Independent Disease
-HLA & Drug Hypersensitivity
1abacavir hypersensitivity (HLA-
B*5701)
2carbamazepine SJS/TEN (HLA-B*1502)
phenytoin SJS/TEN (HLA-B*1502)
3allopurinol SJS/TEN/HSR(HLA-B*5801)
4ximelagatran hepatotoxicity (HLA-
DRB1*07; DQA1*02
5nevirapine rash and rash associated 
hepatitis (class I (HLA-DRB1*0101 + 
CD4+, HLA-B*1402, HLA-Cw8, HLA-
B*3505)
TYPE A TYPE B
1Mallal S et al Lancet 2002;359;727-32
2Chung WH et al. Nature 2004;428:486
Locharenkul et al Epilepsia 2008;49:2087-91
3Shuen-lu Hung et al PNAS 2005;102:4134-9
4Kindmark et al. Pharmacogenomics J 2008;8:186-95
5Martin & al. AIDS 2005;19:97-99; Littera et al. AIDS 2006;1621-6; Gatanga
H et al AIDS 2007;21:264-5; Vitezica et al AIDS 2008;540-1; Chantarangsu
et al Pharmacogent Genomics 2009;9:139-46.HLA & Drug Hypersensitivity
Lancet March 30, 2002
Lancet March 2, 2002Nature 2004Carbamazepine FDA Label Change December 2007published online May 31 2009
PNAS 2005Associations may differ across race, phenotype,  Associations may differ across race, phenotype, 
study design and underlying immune  study design and underlying immune status status
• • HLA HLA- -DRB1*0101 + CD4% > 25 and rash  DRB1*0101 + CD4% > 25 and rash 
associated hepatitis (Martin et al AIDS 2005) associated hepatitis (Martin et al AIDS 2005)
• • HLA HLA- -Cw8 Cw8- -B14 haplotype in Sardinians ( B14 haplotype in Sardinians (Littera Littera et al  et al 
AIDS 2006) AIDS 2006)
• • HLA HLA- -Cw8 in Japanese ( Cw8 in Japanese (Gatanaga Gatanaga et al AIDS 2007 et al AIDS 2007
• • HLA HLA- -DRB1*01 in French population with  DRB1*01 in French population with efavirenz efavirenz
or  or nevirapine nevirapine rash rash Pharmacogenetics & Genomics 2009NEVIRAPINE 
HYPERSENSITIVITY
(rash of varying severity, fever, 
hepatitis, multisystem disease)
Sufficient levels of relevant metabolite
(distinct from dose dependent or “Type A” adverse drug reactions)
•Nevirapine disposition (?Role of CYP3A4/CYP2B6/CYP2C9) and drug transporters (P-glycoprotein(MDR1)) and 
polymorphisms in drug metabolizing and drug transporter genes that differ across ethnicity
Genetic susceptibility conferred by 
Class I  MHC marker(s) eg. HLA-
B*1402, HLA-Cw8, HLA-B*3505
Genetic susceptibility conferred by Class II MHC 
marker(s) eg.  HLA-DRB1*0101
+ Sufficient levels of CD4+ T cells 
•Class II-restricted immune response to NVP-
specific antigen
Class I-restricted immune response to 
NVP-specific antigen
OR
Phillips E, Mallal S.  Current Opinion in Molecular Therapeutics 2009; 11(3);231-242Host-Drug-Infection Interactions: 
A Complex Dynamic
HOST
PATHOGEN DRUG
HLA
Immune response 
genes
Control of infection
Vaccine design
Pharmacodynamics
Pharmacokinetics
Drug Efficacy
Drug Toxicity
Drug resistance
Drug  Efficacy
Chronic persistent DNA viruses 
(CMV, EBV, HHV-6, Herpes 
viruses)
HIVClassic 3 ring Target – HSV not drug
Mucositis & Atypical target
Atypical Target – 2 ring
dusky center 
Blistering of TENHLA-B*1502 & Carbamazepine: 
Phenotype is Important
-associated with severe skin syndromes (SJS/TEN in Han 
Chinese)
-NOT associated with drug hypersensitivity (fever/rash/internal 
organ involvement)  or ?disease in Caucasians
Stevens-Johnson Syndrome/Toxic Epidermal NecrolysisPrerequisites for Widespread 
Incorporation of HLA 
Pharmacogenetic Testing
Implications differ according to drug…Factors Favouring Clinical Uptake of a  Factors Favouring Clinical Uptake of a 
Pharmacogenetic Test Pharmacogenetic Test
• • clinical outcome associated with the test has  clinical outcome associated with the test has 
significant impact on patient significant impact on patient well well- -being being
• • lack of alternative  lack of alternative drug(s drug(s) with more favourable  ) with more favourable 
therapeutic/toxicity profile therapeutic/toxicity profile
• • high predictive value of the genetic test high predictive value of the genetic test
• • ready availability of rapid, low cost test ready availability of rapid, low cost test
• • identification of clinical parameters that determine  identification of clinical parameters that determine 
the usefulness of the test the usefulness of the test
• • sufficient clinical utility to be incorporated into  sufficient clinical utility to be incorporated into 
routine management, so that routine management, so that testing is performed  testing is performed 
prospectively without requiring specific  prospectively without requiring specific ‘ ‘triggers triggers’ ’
Phillips E, Mallal S. Current  Opinion in Infectious Diseases 2008 ;21:16-24Framework of Antiretroviral Therapy &   Framework of Antiretroviral Therapy &  
Pharmacogenetics Pharmacogenetics
• • Define whether or not the drug should  Define whether or not the drug should 
be used (dose independent toxicity) be used (dose independent toxicity)
• • Define the optimal dose of the drug  Define the optimal dose of the drug 
for a specific patient or patient  for a specific patient or patient 
population (dose dependent toxicity &  population (dose dependent toxicity & 
efficacy) efficacy)
• • Avoid drug/drug & drug gene  Avoid drug/drug & drug gene 
interactions interactions
• • Define or enhance understanding of   Define or enhance understanding of  
the pathophysiology of drug toxicity the pathophysiology of drug toxicity
Abacavir Abacavir & HLA & HLA- -B*5701  B*5701 
screening screening
NNRTIs NNRTIs, protease inhibitors , protease inhibitors
Metabolic complications,  Metabolic complications, 
lipodystrophy, peripheral neuropathy,  lipodystrophy, peripheral neuropathy, 
mitochondrial toxicities  mitochondrial toxicities Translating Research in Genomic Medicine into the Clinic & Beyon Translating Research in Genomic Medicine into the Clinic & Beyond d
• • STEP 1  STEP 1 – – The discovery & turning  The discovery & turning 
this into a health application this into a health application
• • STEP 2  STEP 2 - - Development of high level  Development of high level 
clinical evidence (randomized) in  clinical evidence (randomized) in 
support of test. Basic science to  support of test. Basic science to 
support biological plausibility support biological plausibility
• • STEP 3  STEP 3 - - Diffusion of research and  Diffusion of research and 
delivery to clinic depends on  delivery to clinic depends on 
efficiency and quality assurance of  efficiency and quality assurance of 
laboratory testing and reporting laboratory testing and reporting
• • STEP 4  STEP 4 – – Evaluating performance of  Evaluating performance of 
the test in real clinical practice  the test in real clinical practice 
2002  2002 – – HLA HLA- -B*5701 association in two  B*5701 association in two 
independent groups independent groups
2002 2002- -present: genetic and cellular  present: genetic and cellular 
studies support plausibility of  studies support plausibility of 
association association
2005 2005- -2008  2008 – – PREDICT PREDICT- -1, SHAPE &  1, SHAPE & 
observational studies provide robust  observational studies provide robust 
clinical evidence clinical evidence
2005  2005 - - PCR PCR- -based techniques readily  based techniques readily 
applicable methodology (rapid,  applicable methodology (rapid, 
inexpensive)  inexpensive) 
2005 2005- -2008  2008 - - HLA HLA- -B*5701 quality  B*5701 quality 
assurance program roll assurance program roll- -out out
2008  2008 – – HIV Treatment  HIV Treatment 
guidelines/product information change  guidelines/product information change 
to incorporate recommendation for  to incorporate recommendation for 
baseline testing & reimbursement baseline testing & reimbursement
2008 +  2008 + - - Multiple observational studies  Multiple observational studies 
Pharmacoeconomic Pharmacoeconomic evaluation evaluation
Post  Post “ “PREDICT PREDICT- -1 1” ” clinical quality  clinical quality 
assurance assurance
Imprecision of clinical phenotype (false positive clinical diagnosis) cast doubt on 
generalizability of HLA-B*5701 to “all” abacavir HSR. Patch testing developed to identify 
those with true immunologically medicated HSR
Phillips, Mallal  Personalized Medicine 2009 (in press)Pharmacogenetics & Antiretroviral Therapy:   Pharmacogenetics & Antiretroviral Therapy:  
The  The Abacavir Abacavir Example Example
• • Guanosine nucleoside analogue used in antiretroviral therapy, ap Guanosine nucleoside analogue used in antiretroviral therapy, approved  proved 
by regulatory agencies 1998/1999 by regulatory agencies 1998/1999
• • Hypersensitivity syndrome characterized by fever, malaise +/ Hypersensitivity syndrome characterized by fever, malaise +/- - skin rash  skin rash 
was characterized in pre was characterized in pre- -marketing phase, not fatal unless drug  marketing phase, not fatal unless drug 
reintroduced; affected approximately 6 reintroduced; affected approximately 6- - 8% of predominantly Caucasian  8% of predominantly Caucasian 
population population
• • Robust clinical management program for drug Robust clinical management program for drug
• • Early clues such as familial case reports and rarity in Blacks s Early clues such as familial case reports and rarity in Blacks suggested  uggested 
genetic association genetic association
• • 2002  2002 – – two independent groups reported strong association with HLA two independent groups reported strong association with HLA- -
B*5701 B*5701
• • 2008  2008 – – screening for hypersensitivity has rolled out into much of  screening for hypersensitivity has rolled out into much of 
developed world developed worldHLA HLA- -B*5701 B*5701 and  and Abacavir Abacavir
Hypersensitivity: A Comparison  Hypersensitivity: A Comparison 
of Two Studies of Two Studies
*Caucasians only
Observed sensitivity and specificity
PV assumes prevalence of ~9%
Pos Neg
Mallal et al, 2002
HLA-B*5701
Hetherington et al, 2002*
HLA-B57
14 4
5 177
Pos PV Neg PV
74% 98%
HSR
No HSR
Sens 78%
Spec 97%
Pos Neg
36 29
8 649
Pos PV Neg PV
82% 96%
Sens 55%
Spec 99%
Mallal, et al. Lancet 2002;359:727-2.
Hetherington, et al. Lancet 2002;359:1121-2.Early Problems with  Early Problems with “ “Phenotype Phenotype” ”
0
20
40
60
80
100
Mallal CNA30027 CNA30032
White Black
78% 
57%
48%
8%
•Early studies have observed variable sensitivity of 
HLA-B*5701
-Definition of abacavir hypersensitivity reaction (ABC HSR)
nonspecificity of clinical phenotyping Æ
false positive clinical diagnosis
-Differences in white and nonwhite races
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Mallal et al. Lancet 2002
Hughes et al.  Pharmacogenomics 2004Phenotypic Uncertainty of  Phenotypic Uncertainty of Abacavir Abacavir HSR HSR
Blinded Study Blinded Study Abacavir Abacavir
Groups Groups
Zidovudine Zidovudine or  or 
indinavir indinavir
CNA3005 CNA3005 19/268 (7%) 19/268 (7%) 6/265 (2%) 6/265 (2%)
CNA30024 CNA30024 27/324 (8%) 27/324 (8%) 10/325 (3%) 10/325 (3%)
Total Cases Total Cases 46/592 (7.8%) 46/592 (7.8%) 16/590 (2.7%) 16/590 (2.7%)
Cases in CNA30024 as reported by Investigators in the ABC HSR 
CRF Module
Hernandez, et al. ADR/Lipodystrophy 2003.Patch Testing Following ABC Exposure Patch Testing Following ABC Exposure
Local Reaction
ABC Æ Reactive Metabolite (Antigen)
Presentation by epidermal Langerhans cells
Alcohol dehydrogenase
(Abacavir)
Conjugation with host protein in skin
CYP450
Sensitization
CD8+
Prior ABC
ingestion
Day 0 >6 weeks later
Phillips E, Mallal S.  Mol Diag Ther 2009;13:19Abacavir Abacavir Skin Patch Testing Skin Patch Testing
3 previously assigned cases had diagnosis revised
(1) Concurrent NNRTI therapy
(2)  Negative patch test
Patch testing
Previously assigned cases
Carriers of 57.1 AH markers  9/9
Non-57.1 carriers (NNRTI+)  0/3   
Non-57.1 carriers (NNRTI-)  1 patient 
unavailable
ABC HSR
ABC non-HSR Previously assigned tolerant
Carriers of 57.1 AH markers        0/5HLA HLA- -B B* *5701 5701 and  and Abacavir Abacavir
Hypersensitivity Hypersensitivity
Reclassified first 200 patients (*not available)
Martin, et al. PNAS 2004;23;101:4180-5.
Pos Neg
HLA-B*5701
15 1*
4 180
Pos PV Neg PV
78.9% 99.4%
Sens 93.8%
Spec 97.8%
HSR
No HSRIncorporation of a Pharmacogenetic Test  Incorporation of a Pharmacogenetic Test 
into Clinical Practice into Clinical Practice
• • High level evidence  High level evidence generalisable generalisable to diverse clinical  to diverse clinical 
settings settings
• • Widespread availability of cost Widespread availability of cost- -effective and  effective and 
reliable laboratory tests reliable laboratory tests
• • Effective strategies to  Effective strategies to operationalise operationalise testing into  testing into 
routine clinical practice routine clinical practice0.0
0.05
0.10
0.15
0.20
1998/1999 2000/2001 2002/2003 2004 to 7/2005
Possible Abacavir-related 
symptoms, number of
patients
(including definitive ABC-HSR)
Abacavir HSR, number of 
patients
# 2 pts results not reviewed prior
therapy
$ 1 pt with informed choice/
incomplete haplotype
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n=68 n=131 n=107 n=60
#
Before genetic screening After genetic screening
#$ 
*P<0.05
Fall in Early Discontinuation of  Fall in Early Discontinuation of 
Abacavir Abacavir after Introduction of  after Introduction of 
Prospective Genetic Screening* Prospective Genetic Screening*
Rauch, et al. Clin Infect Dis 2006;43:99-102.Other Observational Data Other Observational Data
*Trottier et al  abacavir early discontinuation decreased from 13.6% to 5.6% after 
screening, IAS 2007, abstract MOPEB002)
+HLA-B*5701 + HSR from 12.2% to 0% (Zucman et al JAIDS 2007; epub March 8)
^ABC HSR 6.5% historically to 0% post screening (Reeves et al HIV Medicine March 
2006)
*
0.00%
5.00%
10.00%
15.00%
Prescreen Postscreen
Brighton
France
Canada
CanadaAbacavir Abacavir Hypersensitivity in Clinical Trials Hypersensitivity in Clinical Trials
*All 4/725 (0.8%) patients in ARIES study clinical diagnosed with 
HSR were patch test negative
Wannamaker P et al, World AIDS, Mexico City, AIDS 2008;22(13):1673-5• First RCT to look at clinical utility of a 
pharmacogenetic test to prevent a specific drug 
toxicity
• Problem of false positive clinical diagnosis of 
abacavir hypersensitivity was over come by using 
strategy of skin patch testing (100% specific) to 
define the phenotype of true immunologically
mediated abacavir hypersensitivity
N Eng J Med 2008;358:568-79Prospective, randomized (1:1), double-blind, multicenter study with 6-week 
observation period (>90% of HSR cases)
ABC-naive
subjects (n=1956)
1:1 Randomization
ABC was the only required drug for this study; 
Remainder of regimen was investigator-selected
Patients start ABC (n=913); 
Samples tested for HLA-B*5701
at the end of the study
Only HLA-B*5701-
subjects 
start  ABC (n=859)
HLA-B*5701+ subjects 
excluded from 
study (n=54)
No screening
(n=976)
Samples tested 
for HLA-B*5701
in real time 
(n=980)
If HSR occurs, 
undergo patch 
test 6-8 weeks 
after event
CONTROL
SCREENING 
PREDICT PREDICT- -1 1
Mallal S et al N Eng J Med 2008;358:568-790
1
2
3
4
5
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(
%
)
3.4%
(27/803)
7.8%
(66/847)
2.7%
(23/842)
OR 0.40
P < 0.0001
OR 0.03
P < 0.0001
Control arm
Prospective HLA-B*5701
screening arm
Clinically Suspected
HSR
Immunologically Confirmed
HSR
Clinically Suspected and  Clinically Suspected and 
Immunologically Immunologically Confirmed HSR  Confirmed HSR 
in ITT  in ITT evaluable evaluable population population
0.0%
(0/802)
(0.25, 0.62)
(0, 0.18)Abacavir Exposed >6 weeks 
100%
Clinically suspected 
HSR  7.8%
Patch +‘ve
HSR  2.7%
HLA-B*5701 +’ve
‘True’ HSR (3.1%)
HLA-B*5701 +’ve
ABC Tolerant (2.6%)
N Eng J Med 2008;358:568-79
Phillips E, Mallal S, 
Personalized Medicine 
2009 (in press)INDIA  5-20%
JAPAN  0%
CHINA  0%
(NB 2.5% N.E. 
provinces)
UK 
~8%
MIDDLE EAST  1-2%         
(NB 5-7% Ashkenazi Jews)
AUSTRALIA 
~8%
US 
Caucasian 
~8%
US Asian 
~1%
US 
African-
American 
~2.5%
W. EUROPE  5-7%
THAILAND 
4-10%*
*THAILAND B*57 carriage:
Urban Bangkok 3.6%
Thai Dai Lue (NE Thai) ~11%
Southern Thai Muslim 3%
MEDITERRANEAN 
1-2%
S. AMERICAN 
Caucasian  
5-7%
US 
Hispanic 
~2%
Subsaharan
AFRICA
<1%
HLA HLA- -B*5701 B*5701 Carriage Frequency Carriage Frequency
Phillips E, Clin Infect Dis 2006.SHAPE Study Design SHAPE Study Design
Black and White subjects 
with clinically-suspected
ABC HSR (CS-HSR)
ABC
skin patch test 
& HLA-B*5701
Negative
CASES
Positive
White: 130
Black: 69
White: 42
Black: 5
White: 85
Black: 63
HLA-B*5701 results available for all but one case
Skin patch test results unavailable for 3 Whites, 1 Black
White: 202
Black: 206
HLA-B*5701 results available for all control subjects
Black & White subjects 
enrolled in KLEAN, ALOHA,
CNA30027, CNA30032
Identify ABC-tolerant
subjects who provided
PGx consent and sample
CONTROLS
Black & White subjects 
enrolled in KLEAN, ALOHA,
CNA30027, CNA30032
CONTROLS
Identify ABC-tolerant
subjects who provided
PGx consent and sample
* *Saag Saag et al  et al Clin Clin Infect  Infect Dis Dis 2008 2008;46:1111 ;46:1111- -18 18High Negative Predictive Value of HLA High Negative Predictive Value of HLA- -
B*5701  B*5701 Generalised Generalised Across Race Across Race
SPT-pos
(n=42/42)
100%
CS-HSR
(n=57/130)
44%
Control
(n=194/202)
96%
SPT-pos
(n=5/5)
100%
CS-HSR
(n=10/69)
14%
Control
(n=204/206)
99%
White Black
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OR: White   IC-HSR 1945 [110-34352]; CS-HSR 19[8-48] Black   IC-HSR 900 [30-21045]; CS-HSR 17[4-164]DHHS Guidelines:  http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf: Jan 2008.
IAS Guidelines:  JAMA 2008;300(5):555-70
Preferred Preferred
NNRTI NNRTI EFV EFV ABC/3TC ABC/3TC (for  (for HLA HLA- -B*5701 B*5701 negative patients) or negative patients) or
TDF/FTC TDF/FTC
PI PI FPV/r BID FPV/r BID
LPV/r BID LPV/r BID
ATV/r ATV/r
ABC/3TC ABC/3TC (for  (for HLA HLA- -B*570 B*5701 negative patients) or 1 negative patients) or
TDF/FTC TDF/FTC
Major Treatment Guidelines Revised to  Major Treatment Guidelines Revised to 
Reflect HLA Reflect HLA- -B*5701 Screening B*5701 Screening• • IP IP- - freedom to operate freedom to operate
• • development of  development of  simple,  simple, 
inexpensive,  inexpensive, 
robust,  robust, 
yes/no laboratory tests  yes/no laboratory tests 
and associated  reagents ( and associated  reagents (eg eg monoclonal antibodies) monoclonal antibodies)
• • rapid and simple report and interpretation rapid and simple report and interpretation
• • global distribution and commercialization of allele specific  global distribution and commercialization of allele specific 
test test
• • quality assurance of allele specific test  quality assurance of allele specific test 
• • reimbursement of test reimbursement of test
Prerequisites for Successful Integration of  Prerequisites for Successful Integration of 
HLA  HLA Pharmacogenetic Pharmacogenetic Testing into Routine  Testing into Routine 
Clinical Care:  Laboratory Aspects Clinical Care:  Laboratory Aspects
Phillips E, Mallal S. Curr Opin in Molecular Therapeutics 2009;3:231-42Available Technologies Available Technologies
Cost Cost Turn Turn- -around around- -
time time
Feasibility Feasibility
High resolution  High resolution 
HLA B typing HLA B typing
High High Long (2 weeks  Long (2 weeks 
or more) or more)
Not feasible  Not feasible 
unless specialty  unless specialty 
laboratory laboratory
PCR PCR- -based  based 
techniques techniques
Moderate  Moderate 
(<$100 USD) (<$100 USD)
Moderate (<2  Moderate (<2 
week) week)
Feasible for labs  Feasible for labs 
with molecular  with molecular 
technologies technologies
B17 B17- -monoclonal  monoclonal 
Flow Cytometry Flow Cytometry
Low Low Low (mandated  Low (mandated 
by need for fresh  by need for fresh 
cells) cells)
For labs doing  For labs doing 
CD4+/8  CD4+/8 
Phillips E, Mallal S.  Mol Diag Ther 2009;13:1-9Pharmacogenetics and HLA: 
Predicting the Unpredictable?
• Type A reactions are predictable based on their 
pharmacological action therefore pharmacogenetic factors 
will only explain a proportion of the variability in drug 
response
• Type B adverse drug reactions such as hypersensitivity 
reactions and severe skin syndromes are 
immunogenetically mediated 
• HLA associations are promising for prediction and hence 
prevention of these types of reactions but abacavir is 
currently the only drug where high level evidence exists and 
widespread screening has been implemented
• Numerous clinical and laboratory hurdles must be overcome 
for successful integration of pharmacogenetic testing into a 
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